Alcon buys Neurotech for $550 million upfront

Alcon, the Swiss eye‑care company, announced it has completed the acquisition of Neurotech Pharmaceuticals.

The transaction includes an upfront cash payment of $550 million, with the possibility of additional contingent payments tied to future milestones.

The acquisition adds Neurotech’s FDA‑approved assets to Alcon’s portfolio, bolstering its position in the ophthalmology market.